InVivoMAb anti-mouse CD27

Ahrends T, Spanjaard A, Pilzecker B, et al. CD4(+) T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity. 2017,47(5):848-861.e5. doi: 10.1016/j.immuni.2017.10.009

Ngiow SF, Young A, Blake SJ, et al. Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer Res. 2016,76(21):6266-6277.

Ahrends T, Bąbała N, Xiao Y, et al. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016,76(10):2921-31. doi: 10.1158/0008-5472.CAN-15-3130

Roberts DJ, Franklin NA, Kingeter LM, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother. 2010,33(8):769-79. doi: 10.1097/CJI.0b013e3181ee238f

Sakanishi T, Yagita H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun. 2010,393(4):829-35. doi: 10.1016/j.bbrc.2010.02.092

Sumi T, Ishida W, Ojima A, et al. CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in mice. Immunol Lett. 2008,119(1-2):91-6. doi: 10.1016/j.imlet.2008.05.004